To evaluate the LAPTM4B levels and efficacy of adjuvant therapy, we investigated 330 BC patients undergoing their adjuvant therapy cycles in Beijing Cancer Hospital, including 191 endocrine therapy, 106 chemotherapy or radiotherapy, and 33 anti-HER2 therapy. This evidence concerns the gene ERBB2 and breast cancer.